Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sangamo Therapeutics (SGMO) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 289,560
  • Shares Outstanding, K 70,620
  • Annual Sales, $ 39,540 K
  • Annual Income, $ -40,700 K
  • 36-Month Beta 3.26
  • Price/Sales 14.25
  • Price/Book 1.94

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.85 +28.07%
on 12/28/16
4.45 -17.98%
on 01/13/17
+0.40 (+12.31%)
since 12/20/16
3-Month
2.65 +37.74%
on 12/08/16
4.60 -20.65%
on 11/14/16
-0.20 (-5.19%)
since 10/20/16
52-Week
2.65 +37.74%
on 12/08/16
7.60 -51.97%
on 06/07/16
-2.62 (-41.79%)
since 01/20/16

Most Recent Stories

More News
Sangamo Therapeutics Receives Orphan Drug Designation from the FDA for SB-318 Genome Editing Treatment for MPS I

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SB-318, a genome...

Sangamo BioSciences Changes Name To Sangamo Therapeutics, Underscoring Focus On Clinical Development Of Genomic Therapies

Sangamo Therapeutics, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announces that it has changed its corporate name, from "Sangamo BioSciences, Inc." to "Sangamo Therapeutics, Inc." Sangamo...

Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy Program For Hemophilia A

Sangamo BioSciences, Inc. (NASDAQ: SGMO) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug application (IND) for its SB-525 gene therapy...

Sangamo BioSciences Announces Presentation At The 35th Annual J.P. Morgan Healthcare Conference

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D, Sangamo's chief executive officer, will participate in the 35th...

Commit To Buy Sangamo BioSciences At $2, Earn 19.2% Annualized Using Options

Investors considering a purchase of Sangamo BioSciences Inc shares, but cautious about paying the going market price of $2.95/share, might benefit from considering selling puts among the alternative strategies...

Sangamo's Genome Editing Program for Hemoglobinopathies to Transfer to Biogen's Spin-Off Bioverativ

Sangamo BioSciences, Inc. (Nasdaq: SGMO), a leader in therapeutic genome editing, announced today that its collaborative zinc finger nuclease (ZFN)-mediated genome editing program for hemoglobinopathies...

Biotech Stocks on Investors' Radar -- Inovio Pharma, Pacific Biosciences of California, BioCryst Pharma, and Sangamo Biosciences

In today's pre-market research, Stock-Callers.com reviews the performances of four Biotech equities at the close: Inovio Pharmaceuticals Inc. (NASDAQ: INO), Pacific Biosciences of California Inc. (NASDAQ:...

Sangamo BioSciences Announces Participation At Upcoming Investor Conferences

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, announced today that Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's president and chief executive officer, will participate...

Downgrade Alert for Sangamo Biosciences (SGMO)

Sangamo Biosciences (NASDAQ:SGMO) was downgraded from Outperform to Neutral at Wedbush today. The stock closed yesterday at $3.65 on volume of 1.0 million shares, above average daily volume of 770,000....

Sangamo BioSciences Reports Third Quarter 2016 Financial Results

Sangamo BioSciences, Inc. (NASDAQ: SGMO), the leader in therapeutic genome editing, today reported its third quarter 2016 financial results and provided an update on recent events and development timelines...

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Weakening.

See More

Business Summary

Sangamo BioSciences, Inc. is a leader in the development of noveltranscription factors for the regulation of gene expression. Transcriptionfactors are proteins that turn genes on or off by recognizing specific DNAsequences. The Universal Gene Recognition technology platform enables theengineering of...

See More

Support & Resistance

2nd Resistance Point 4.12
1st Resistance Point 3.88
Last Price 3.65
1st Support Level 3.53
2nd Support Level 3.42

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.